RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

OK, I see your point. But the territories don't overlap. As I recall it (which could be off...), the 'two indication' question was--Could CX-1739 be licensed to one company for RD, and a different one for ADHD--in North America...

Would acceptance of the geographical split be affected if the indications differed? Offhand, I can't think of an example where that's occurred, and I suppose one could argue that a US partner might worry about elderly Korean patients receiving the same drug for AD or PD. But the principle of splitting off Asia is so embedded that I don't think this would be a significant issue. I look forward to the day that a US partnering prospect is so interested in an Ampakine that they'd give any thought to the question.

NeuroInvestment